Testing an immune-boosting cancer drug for rare genetic tumor types

This trial is testing atezolizumab, a medication that helps your immune system fight cancer, in people with rare cancers or common cancers that have specific genetic changes (high tumor mutation burden, microsatellite instability, or mismatch repair deficiency). The study includes adults, children, and teenagers across many different cancer types. The goal is to find out whether this medication works for these hard-to-treat groups and eventually make it available through the NHS.

Most cancer drugs are tested in large groups of common cancers, which means people with rare cancers often have very few treatment options. This trial exists to see if this medication can help people whose cancers have specific genetic features that might make them respond to this type of treatment—opening up new possibilities for patients who currently have limited choices.